Af­ter land­ing a his­toric FDA OK, Al­ny­lam chief John Maraganore scores a big raise

It took more than 15 years all told, but last year Al­ny­lam $AL­NY fi­nal­ly made the big leap in­to com­mer­cial­iz­ing the first of the RNAi drugs that it had been de­vel­op­ing. And CEO John Maraganore and his top team at the bell­wether biotech en­joyed a mul­ti­mil­lion-dol­lar wind­fall on their suc­cess.

Maraganore isn’t com­pet­ing for a place in the top 15 by any means. But he earned a com­pen­sa­tion pack­age worth a lit­tle more than $5 mil­lion — most of it in op­tion awards — which is well un­der the $7.7 mil­lion earned by Em­ma Walm­s­ley, who cur­rent­ly holds the bot­tom rung of the Big Phar­ma com­pen­sa­tion lad­der for 2018.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.